From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC: A novel selective broad-spectrum anti-DNA virus agent. Nature323,464–467 (1986).•• First paper describing the antiviral activity of the acyclic nucleoside phosphonates (ANPs) with a prototype 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, from which all ANPs (e.g., adefovir, cidofovir and tenofovir) were derived.
  Medline CASGoogle Scholar
• 2  Pauwels R, Balzarini J, Schols D et al.: Phosphonylmethoxyethyl purine derivatives: a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother.32,1025–1030 (1988).
  Medline CASGoogle Scholar
• 3  Balzarini J, Naesens L, Herdewijn P et al.: Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective antihuman immunodeficiency virus agent. Proc. Natl Acad. Sci. USA86,332–336 (1989).
  Medline CASGoogle Scholar
• 4  Balzarini J, Holý A, Jindrich J et al.: 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo.Proc. Natl Acad. Sci. USA88,4961–4965 (1991).
  Medline CASGoogle Scholar
• 5  Balzarini J, Holý A, Jindrich J et al.: Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of(R)-9-(2-phosphonomethoxypropyl)- 2,6-diaminopurine. Antimicrob. Agents Chemother.37,332–338 (1993).•• First paper describing the anti-HIV activity of tenofovir, later to become a key component in anti-HIV combination regimens.
  Medline CASGoogle Scholar
• 6  Balzarini J, Aquaro S, Perno CF, Witvrouw M, Holý A, De Clercq E: Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Commun.219,337–341 (1996).
  Medline CASGoogle Scholar
• 7  Naesens L, Bischofberger N, Augustijns P et al.: Antiretroviral efficacy and pharmacokinetics of oral bis-(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob. Agents Chemother.42,1568–1573 (1998).• Together with [8], was the first to describe the anti-HIV activity and efficacy of tenofovir disoproxil.
  Medline CASGoogle Scholar
• 8  Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A: Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother.42,612–617 (1998).• Together with [7], was the first to describe the anti-HIV activity and efficacy of tenofovir disoproxil.
  Medline CASGoogle Scholar
• 9  De Clercq E, Holý A: Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discovery4,928–940 (2005).•• History on how the ANPs originated and evolved to their present state as antiviral drugs for the treatment of DNA virus and retrovirus infections.
  Medline CASGoogle Scholar
• 10  Helliot B, Panis B, Frison E et al.: The acyclic nucleoside phosphonate analogues, adefovir, tenofovir and PMEDAP, efficiently eliminate banana streak virus from banana (Musa spp.). Antiviral Res.59,121–126 (2003).• A side observation that needs to be followed up in a socio-economic context totally different from, but tangential to, the AIDS context.
  Medline CASGoogle Scholar
• 11  Suo Z, Johnson KA: Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-phosphonylmethoxypropyl)adenine. J. Biol. Chem.273,27250–27258 (1998).
  Medline CASGoogle Scholar
• 12  Cherrington JM, Allen SJW, Bischofberger N, Chen MS: Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β and γ. Antiviral Chem. Chemother.6,217–221 (1995).
  CASGoogle Scholar
• 13  Cihlar T, Chen MS: Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA byhuman DNA polymerases α, β and γ. Antiviral Chem. Chemother.8,187–195 (1997).
  CASGoogle Scholar
• 14  Birkus G, Hitchcock MJM, Cihlar T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother.46,716–723 (2002).
  Medline CASGoogle Scholar
• 15  Biesecker G, Karimi S, Desjardins J et al.: Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Res.58,217–225 (2003).
  Medline CASGoogle Scholar
• 16  Gallant JE, Staszewski S, Pozniak AL et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA292,191–201 (2004).
  Medline CASGoogle Scholar
• 17  Domingo P, Labarga P, Palacios R et al.: Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS18,1475–1478 (2004).
  MedlineGoogle Scholar
• 18  Moyle G, Sabin C, Cartledge J et al.:A 48-week, randomized, open-label comparative study of tenofovir DF versus abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. Presented at: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22–25 February 2005.
  Google Scholar
• 19  Izzedine H, Hulot JS, Vittecoq D et al.: Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data froma double-blind randomizedactive-controlled multicentre study. Nephrol. Dial. Transplant.20,743–746 (2005).
  Medline CASGoogle Scholar
• 20  Gallant JE, DeJesus E, Arribas JR et al.: Tenofovir DF, emtricitabine, and efavirenz versus zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med.354,251–260 (2006).•• Of pivotal importance in the development of the combination pill consisting of tenofovir disoproxil fumarate (TDF), emtricitabine and efavirenz for the treatment of HIV infections.
  Medline CASGoogle Scholar
• 21  Schooley RT, Ruane P, Myers RA et al.: Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS16,1257–1263 (2002).
  Medline CASGoogle Scholar
• 22  Squires K, Pozniak AL, Pierone G Jr et al.: Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann. Intern. Med.139,313–320 (2003).
  Medline CASGoogle Scholar
• 23  Nelson M, Cooper D, Schooley R et al.: The safety of tenofovir DF for the treatment of HIV infection: the first 4 years. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006.
  Google Scholar
• 24  Miller MD, Margot N, Lu B et al.: Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis.189,837–846 (2004).
  Medline CASGoogle Scholar
• 25  White KL, Margot NA, Ly JK et al.: A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS19,1751–1760 (2005).
  Medline CASGoogle Scholar
• 26  Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD: Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS16,1227–1235 (2002).
  Medline CASGoogle Scholar
• 27  Deval J, White KL, Miller MD et al.: Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem.279,509–516 (2004).
  Medline CASGoogle Scholar
• 28  Frankel F, Turner D, Spira B, Wainberg M: Molecular characterization of HIV-1 reverse transcriptase harboring the K65R and L74V mutations. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006.
  Google Scholar
• 29  Weber J, Chakraborty B, Weberova J, Miller MD, Quinones-Mateu ME: Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J. Clin. Microbiol.43,1395–1400 (2005).
  Medline CASGoogle Scholar
• 30  White KL, Chen JM, Feng JY et al.: The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antiviral Ther.11,155–163 (2006).
  Medline CASGoogle Scholar
• 31  Sluis-Cremer N, Torres PA, Grzybowski J, Parikh U, Mellors J: Molecular mechanism of tenofovir, abacavir, and lamivudine resistance by the K70E mutation in HIV-1 reverse transcriptase. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006.
  Google Scholar
• 32  Kearney BP, Flaherty JF, Shah J: Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet.43,595–612 (2004).
  Medline CASGoogle Scholar
• 33  León A, Mallolas J, Martinez E et al.: High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir. AIDS19,1695–1706 (2005).
  Medline CASGoogle Scholar
• 34  Maitland D, Moyle G, Hand J et al.: Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS19,1183–1188 (2005).
  Medline CASGoogle Scholar
• 35  Gallant JE, Rodriguez AE, Weinberg WG et al.: Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naivesubjects. J. Infect. Dis.192,1921–1930 (2005).
  Medline CASGoogle Scholar
• 36  Hawkins T, Veikley W, St Claire RL 3rd, Guyer B, Clark N, Kearney BP: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr.39,406–411 (2005).
  Medline CASGoogle Scholar
• 37  Lanier ER, Hazen R, Ross L, Freeman A, Harvey R: Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1. J. Acquir. Immune Defic. Syndr.39,519–522 (2005).
  Medline CASGoogle Scholar
• 38  Ray AS, Myrick F, Vela JE et al.: Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antiviral Ther.10,451–457 (2005).
  Medline CASGoogle Scholar
• 39  Delaunay C, Brun-Vézinet F, Landman R et al.: Comparative selection of the K65R and M184V/I mutations in human imunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J. Virol.79,9572–9578 (2005).
  Medline CASGoogle Scholar
• 40  Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G: Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin. Infect. Dis.42,283–290 (2006).
  Medline CASGoogle Scholar
• 41  Tsai CC, Follis KE, Sabo A et al.: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science270,1197–1199 (1995).•• Pioneering observation describing the potential value of tenofovir in the prevention of HIV infections, heralded in the present study by the prevention of simian immunodeficiency virus infection in rhesus macaques, and later followed up by similar prophylactic studies in macaques [42,43].
  Medline CASGoogle Scholar
• 42  Otten RA, Smith DK, Adams DR et al.: Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J. Virol.74,9771–9775 (2000).
  Medline CASGoogle Scholar
• 43  Van Rompay KK, McChesney MB, Aguirre NL, Schmidt KA, Bischofberger N, Marthas ML: Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J. Infect. Dis.184,429–438 (2001).
  Medline CASGoogle Scholar
• 44  Mayer KH, Maslankowski LA, Gai F et al.: Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS20,543–551 (2006).
  Medline CASGoogle Scholar
• 45  Garcia-Lerma J, Otten R, Qari S et al.: Prevention of rectal SHIV transmission in macaques by tenofovir/FTC combination. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006.
  Google Scholar
• 46  Johnson J, Van Rompay K, Delwart E, Heneine W: Rapid emergence of drug-resistant SIV in tenofovir-treated macaques: implications for tenofovir chemoprophylaxis against HIV. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006.
  Google Scholar
• 47  Benhamou Y, Fleury H, Trimoulet P et al.: Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology43,548–555 (2006).• Study pertaining to the role of TDF in the treatment of chronic hepatitis B in hepatitis B virus (HBV)/HIV coinfected patients.
  Medline CASGoogle Scholar
• 48  Nelson M, Bhagani S, Fisher M et al.: A 48-week study of tenofovir or lamivudine or a combination of tenofovir and lamivudine for the treatment of chronic hepatitis B in HIV/HBV coinfected individuals. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006.
  Google Scholar
• 49  Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE 4th: Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antiviral Ther.10,625–633 (2005).
  Medline CASGoogle Scholar
• 50  Delaney WE 4th, Ray AS, Yang H et al.: Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother.50,2471–2477 (2006).
  Medline CASGoogle Scholar
• 51  Schildgen O, Sirma H, Funk A et al.: Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med.354,1807–1812 (2006).• Study suggesting the potential of TDF in the treatment of chronic hepatitis B in HBV/HIV co-infected patients.
  Medline CASGoogle Scholar